Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer.
It was found that renal cancer tissue is characterized by increased content of VEGF not depending on the parameters of normal tissue and expression of VEGFR2 receptor. At the same time, the content of VEGFR2 in the tumor is determined by the state of the surrounding tissue and increases in low number of patients with tumors invading the renal capsule. Serum concentrations of VEGF and VEGFR2 in patients with renal cancer did not significantly differ from the corresponding values in the control group. No significant correlations between the levels of VEGF and VEGFR2 in the blood and tumor tissue were found.
Kushlinsky
N E
NE
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences; M. F. Vladimirskii Research Clinical Institute of Moscow Region, Moscow, Russia.
Trapeznikova
M F
MF
Gershtein
E S
ES
Glibin
P A
PA
Kazantceva
I A
IA
Kilichbekov
M B
MB
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood / Q000378:metabolism*
D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2